Oxygen Biotherapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 25   

Articles published

OXBT 5.14 -0.08 (-1.53%)
price chart
Oxygen Biotherapeutics, Inc. Analyst Report: Positive FDA Catalyst Has ...
NEW YORK, April 21, 2014 /PRNewswire/ -- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue.
Related articles »  
Oxygen Biotherapeutics Inc., Announces the Appointment of Industry Veteran ...
MORRISVILLE, N.C., Apr 04, 2014 (BUSINESS WIRE) -- Oxygen Biotherapeutics, Inc., (NASDAQ:OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that ...
Related articles »  
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the ...
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has received written confirmation from the Food and ...
Related articles »  
FDA confirms lifting of clinical hold on Oxygen Bio's Oxycyte
Oxygen Biotherapeutics (OXBT) has received written confirmation that the FDA has lifted a hold on the clinical trials of the company's Oxycyte treatment for traumatic brain injury.
Upbeat Stocks At Street: Oxygen Biotherapeutics Inc. (OXBT), Universal ...  Techsonian (press release)
Oxygen Biotherapeutics Up on FDA News  Zacks.com
Related articles »  
Recently Released Market Study: Oxygen Biotherapeutics, Inc. - Mergers ...
MarketLines' Oxygen Biotherapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital ...
Related articles »  
Biotech Bullish Stocks: Oxygen Biotherapeutics (NASDAQ:OXBT), MediciNov ...
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) announced Monday that it has written U.S. Food and Drug Administration confirmation that a clinical hold has been removed on development of its treatment for traumatic brain injury, decompression sickness and ...
Pre-Market Buzz: Tesla Motors Inc (NASDAQ:TSLA), Oxygen Biotherapeutics ...
Tesla Motors Inc(NASDAQ:TSLA)'s general manager in China has left the company as the electric carmaker gears up to take a foothold in the world's largest auto market.
Related articles »  
Stocks to Track-Arena Pharmaceuticals, Inc. (ARNA), Oxygen Biotherapeutics ...
Las Vegas, NV - April 01, 2014 - (TechSonian) - Arena Pharmaceuticals, Inc. (ARNA) offered a corporate update and reported financial results for the 4th quarter and full year ended 31st December, 2013.
Related articles »  
Biotech Losers: Cytokinetics (NASDAQ:CYTK), Ultragenyx Pharmaceutical ...
Mr. Proehl was the designee selected by Phyxius Pharma, Inc. Stockholders and his appointment as a director consummated one of the terms of the Phyxius Acquisition.
Healthcare Gainers: Insmed (NASDAQ:INSM), CytRx Corporation (NASDAQ ...
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) announced that it has written U.S. Food and Drug Administration confirmation that a clinical hold has been removed on development of its treatment for traumatic brain injury, decompression sickness and stroke.
Related articles »